

IT IS CLAIMED:

1. A peptide selected from the group consisting of δ V1-1 (SEQ ID NO:4), δ V1-2 (SEQ ID NO:5), $\psi\delta$ RACK (SEQ ID NO:6), δ V1-5 (SEQ ID NO:7), and derivatives and fragments thereof.
2. The peptide of claim 1 wherein the derivative is selected from the group consisting of δ V1-1 derivatives identified as SEQ ID NOS:34-48.
3. The peptide of claim 1 wherein the derivative is selected from the group consisting of δ V1-2 derivatives identified as SEQ ID NOS:65-71.
4. The peptide of claim 1, wherein the derivative is selected from the group consisting of $\psi\delta$ RACK derivatives identified as SEQ ID NOS:11-19, 22-33.
5. The peptide of claim 1, wherein the fragment has the sequence selected from the group identified as SEQ ID NOS:49-64.
6. The peptide of claim 1, wherein the fragment has the sequence selected from the group identified as SEQ ID NO:20 and SEQ ID NO:21.
7. The peptide according to claim 1, wherein said peptide is recombinantly produced.
8. The peptide of claim 1, wherein the peptide is chemically synthesized.
9. The peptide of claim 1, wherein the peptide is encoded by a polynucleotide.
10. The peptide of claim 1, wherein the peptide is linked to a moiety effective to facilitate transport across a cell membrane.
11. The peptide of claim 10, wherein the peptide is linked to a moiety selected from the group consisting of a Tat-derived peptide, an Antennapedia carrier peptide, and a polyarginine peptide.

12. The peptide of claim 1 joined to a second peptide to form a fusion peptide.
13. A method of reducing ischemic injury to a cell or a tissue exposed to hypoxic conditions, comprising
 - 5 administering to the cell or tissue an amount of a δ PKC antagonist.
 14. The method of claim 13, wherein said administering occurs prior to exposing the cell or tissue to said hypoxic conditions.
 - 10 15. The method of claim 13, wherein said administering occurs during exposing the tissue to said hypoxic conditions.
 16. The method of claim 13, wherein said administering occurs after exposing the tissue to said hypoxic conditions.
 - 15 17. The method of claim 13, wherein said administering includes administering an antagonist selected from the group consisting of δ V1-1 (SEQ ID NO:4), δ V1-2 (SEQ ID NO:5), δ V1-5 (SEQ ID NO:7), and derivatives and fragments thereof.
 - 20 18. The method of claim 17, wherein said administering includes administering a δ V1-1 derivative antagonist selected from the group consisting of SEQ ID NOS:34-48.
 19. The method of claim 17, wherein said administering includes administering a δ V1-2 derivative antagonist selected from the group consisting of SEQ ID NOS:65-71.
 - 25 20. The method of claim 17, wherein said administering includes administering a peptide fragment selected from the group of peptides identified as SEQ ID NOS:49-64.
 21. The method of claim 13, wherein said administering includes administering a peptide linked to a moiety effective to facilitate transport across a cell membrane.
 - 30 22. The method of claim 13, wherein said administering includes administering a peptide linked to a moiety selected from the group consisting of a Tat-derived peptide, an Antennapedia carrier peptide, and a polyarginine peptide.

23. The method of claim 13, wherein said administering is by infusion through coronary arteries to an intact heart.

24. A method of reducing damage to a cell or tissue from a hypoxic event due to stroke,
5 comprising

administering to the cell or tissue an amount of a δ PKC antagonist.

25. The method of claim 24, wherein said administering occurs prior to said hypoxic event.

26. The method of claim 24, wherein said administering occurs during exposing the tissue to said hypoxic event.

27. The method of claim 24, wherein said administering occurs after exposing the tissue to said hypoxic event.

28. The method of claim 24, wherein said administering includes administering an antagonist selected from the group consisting of δ V1-1 (SEQ ID NO:4), δ V1-2 (SEQ ID NO:5), δ V1-5 (SEQ ID NO:7), and derivatives and fragments thereof.

29. The method of claim 28, wherein said administering includes administering a δ V1-1 derivative antagonist selected from the group consisting of SEQ ID NOS:34-48.

30. The method of claim 28, wherein said administering includes administering a δ V1-2 derivative antagonist selected from the group consisting of SEQ ID NOS:65-71.

31. The method of claim 28, wherein said administering includes administering a peptide fragment selected from the group of peptides identified as SEQ ID NOS:49-64.

32. The method of claim 24, wherein said administering includes administering a peptide linked to a moiety effective to facilitate transport across a cell membrane.

33. The method of claim 24, wherein said administering includes administering a peptide linked to a moiety selected from the group consisting of a Tat-derived peptide, an

Antennapedia carrier peptide, and a polyarginine peptide.

34. A method of enhancing damage to a cell exposed to hypoxic conditions, comprising administering to the cell an amount of an isozyme-specific δ PKC agonist.

5

35. The method of claim 34, wherein the agonist is $\psi\delta$ RACK identified as SEQ ID NO:6, a derivative or a fragment thereof.

10

36. The method of claim 34, wherein the agonist is a peptide selected from the group consisting of SEQ ID NOS:11-19, and SEQ ID NOS:22-29.

37. The method of claim 34, wherein the agonist is a peptide selected from the group consisting of SEQ ID NOS:20-21.

15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995

38. The method of claim 34, wherein the cell is a tumor cell.

39. The method of claim 34, wherein said agonist is linked to a moiety effective to facilitate transport across a cell membrane.

40. A method of identifying a compound effective to induce protection of a cell from hypoxic or ischemic damage, comprising

contacting a δ PKC peptide containing a δ RACK binding site with a δ PKC antagonist peptide with the δ RACK binding site in the presence and absence of said test compound, and

25

identifying said test compound as being effective to induce protection if (i) binding in the presence of the test compound is decreased relative to binding in the absence of the test compound, or (ii) catalytic activity of the test compound is increased relative to activity in the absence of the test compound.

30

41. The method of claim 40, wherein said contacting includes contacting a δ PKC peptide selected from the group consisting of δ V1-1 (SEQ ID NO:4), δ V1-2 (SEQ ID NO:5), δ V1-5 (SEQ ID NO:7, and fragments and derivatives thereof.

42. The method of claim 39, wherein said contacting includes contacting with δ PKC antagonist peptide selected from the group consisting of SEQ ID NO:34-48.

43. The method of claim 39, wherein said contacting includes contacting with δ PKC antagonist peptide selected from the group consisting of SEQ ID NO:49-64.

44. The method of claim 39, wherein said contacting includes contacting with δ PKC antagonist peptide selected from the group consisting of SEQ ID NO:65-71.

45. The method of claim 39, wherein said δ PKC peptide containing a δ RACK binding site is identified as SEQ ID NO:72.

46. A method of identifying a compound effective to enhance hypoxic or ischemic damage in a cell, comprising
 contacting a ψ δ RACK agonsit peptide with a δ PKC peptide containing a RACK binding site in the presence and absence of a test compound, and
 identifying said test compound as being effective to enhance ischemic damage if (i) binding in the presence of the test compound is decreased relative to binding in the absence of the test compound, or (ii) the catalytic activity of the δ PKC in the presence of the test compound is increased relative to the catalytic activity in the absence of the test compound.

47. The method of claim 46, wherein said contacting includes contacting with a ψ δ RACK peptide selected from the group consisting of SEQ ID NO:6, fragments, and derivatives thereof.

48. The method of claim 46, wherein said contacting includes contacting with a ψ δ RACK peptide having a sequence selected from the group of peptides identified as SEQ ID NOS:11-19 and SEQ ID NOS:22-29.

49. The method of claim 46, wherein said contacting includes contacting with a ψ δ RACK peptide fragment having a sequence selected from the group of peptides identified as SEQ ID NOS:20-21.

50. A method of providing protection to tissue from damage caused by an ischemic or hypoxic event, comprising
 administering to the tissue a peptide selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:7, derivatives and fragments thereof.

5

51. The method of claim 50, wherein said administering includes administering a peptide derivative selected from the group consisting of δ V1-1 derivatives identified as SEQ ID NO:34-47.

10

52. The method of claim 50, wherein said administering includes administering a peptide derivative selected from the group consisting of δ V1-2 derivatives identified as SEQ ID NO:65-71.

15
 20
 25
 30
 35
 40
 45
 50
 55
 60
 65
 70
 75
 80
 85
 90
 95
 100
 105
 110
 115
 120
 125
 130
 135
 140
 145
 150
 155
 160
 165
 170
 175
 180
 185
 190
 195
 200
 205
 210
 215
 220
 225
 230
 235
 240
 245
 250
 255
 260
 265
 270
 275
 280
 285
 290
 295
 300
 305
 310
 315
 320
 325
 330
 335
 340
 345
 350
 355
 360
 365
 370
 375
 380
 385
 390
 395
 400
 405
 410
 415
 420
 425
 430
 435
 440
 445
 450
 455
 460
 465
 470
 475
 480
 485
 490
 495
 500
 505
 510
 515
 520
 525
 530
 535
 540
 545
 550
 555
 560
 565
 570
 575
 580
 585
 590
 595
 600
 605
 610
 615
 620
 625
 630
 635
 640
 645
 650
 655
 660
 665
 670
 675
 680
 685
 690
 695
 700
 705
 710
 715
 720
 725
 730
 735
 740
 745
 750
 755
 760
 765
 770
 775
 780
 785
 790
 795
 800
 805
 810
 815
 820
 825
 830
 835
 840
 845
 850
 855
 860
 865
 870
 875
 880
 885
 890
 895
 900
 905
 910
 915
 920
 925
 930
 935
 940
 945
 950
 955
 960
 965
 970
 975
 980
 985
 990
 995
 1000

53. The method of claim 50, wherein said administering includes administering a peptide fragment selected from the group consisting of peptides identified as SEQ ID NOS:49-64.

54. The method of claim 50, wherein said administering includes administering a peptide linked to a moiety effective to facilitate transport across a cell membrane.

55. The method of claim 54, wherein said administering includes administering a peptide linked to a moiety selected from the group consisting of a Tat-derived peptide, an Antennapedia carrier peptide, and a polyarginine peptide.

25

56. The method of claim 50, wherein said administering includes administering the peptide by a route selected from the group consisting of intravenous, parenteral, subcutaneous, inhalation, intranasal, sublingual, mucosal, and transdermal.

57. The method of claim 50, wherein said administering occurs during reperfusion.

30

58. The method of claim 50, wherein said administering is effective to provide protection against ischemia of a tissue selected from the group consisting of brain, heart, eye, and kidney.